Soc. Generale Knock-Out IPN/ DE000SU5ZS09 /
| 2024-08-30 8:14:30 AM | Chg.-0.05 | Bid10:00:38 PM | Ask10:00:38 PM | Underlying | Strike price | Expiration date | Option type |
|---|---|---|---|---|---|---|---|
| 1.93EUR | -2.53% | - Bid Size: - |
- Ask Size: - |
Ipsen SA | 147.5853 EUR | 2078-12-31 | Put |
GlobeNewswire
08-13
Sutro Biopharma Reports Second Quarter 2024 Financial Results, Business Highlights and Select Antici...
GlobeNewswire
07-26
GENFIT: Positive Opinion from EMA Committee for Ipsen’s Iqirvo® (elafibranor) in Primary Biliary Cho...
GlobeNewswire
07-26
Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and K...
GlobeNewswire
07-25
Ipsen delivers strong results in the first half of 2024, progresses on launches and upgrades its ful...
GlobeNewswire
07-25
Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for ...
GlobeNewswire
07-11
Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug con...
GlobeNewswire
07-04
HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refract...
GlobeNewswire
07-02
Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroend...
GlobeNewswire
06-17
GENFIT: New EASL-EASD-EASO Clinical Practice Guidelines for MASLD Include NIS2+® as Key Tool for Det...
GlobeNewswire
06-11
Skyhawk Therapeutics Promotes Clint Musil to Chief Executive Officer and Appoints Co-founder Bill Ha...
GlobeNewswire
06-10
GENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen’s Iqirvo® for Primar...
GlobeNewswire
06-10
Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primar...
GlobeNewswire
06-07
Ipsen and Marengo Therapeutics announce second strategic partnership to advance precision T cell eng...
GlobeNewswire
06-05
Ipsen presents long-term elafibranor efficacy and itch-related quality of life data in patients with...
